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Abstract: The value of collaborations and partnerships between different stakeholders to achieve optimum outcomes in 
the medicines research and development process is being recognised. Historically, there has been a lack of collaboration 
with patients and many research consortiums consisting mainly of academia and/or industry partners. Although patient 
experts are able to bring valuable first-hand experience and insights, they might not possess detailed knowledge about 
medicines research and development to actively participate in the collaboration process. The European Patients’ Acad-
emy on Therapeutic Innovation (EUPATI) was established to deliver training to patient experts, and education resources 
to patient advocates and members of the health-interested public across Europe. EUPATI was launched in February 
2012 and is a patient-led Innovative Medicines Initiative (IMI) project, with a multi-stakeholder consortium of patient 
advocates, academia, industry and not-for-profit organisations. Training and educational materials will be used for ca-
pacity building among patients, for educating patient advocates and for informing the health-interested public. The suc-
cessful uptake of EUPATI’s materials will hopefully translate into a new paradigm of increased patient involvement 
across the entire medicines research and development process, bringing mutual benefits, including better medicines, to 
all stakeholders. 
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1. Introduction: The Era of Partnerships 
raditionally, research in medicines develop-
ment has been conducted internally within 
companies intending to develop new medicines. 
Due to concerns such as intellectual property and data 
protection, partnerships were often lacking. However,  
in current times of rising costs and scarce resources, 
the value of collaborations and partnerships between 
different stakeholders to achieve an optimum outcome 
is becoming more apparent. There have been several 
cases of industry−academia collaborations. Some 
challenges in these collaborations include an align-
ment of priorities between universities and businesses,  
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but overcoming such challenges is possible and can 
lead to accelerated results. For example, Pfizer and 
University of California, San Diego, have combined 
teams of university and industry scientists with drug 
development expertise[1]. Similarly, the University of 
Cambridge has placed academic scientists into the 
laboratories on GSK research campus in the UK[2]. 
However, in the field of medicines research and 
development (R&D), collaborations between patients 
and other stakeholders have been neither usual nor 
frequent. This is probably due to the fact that histori-
cally there has been public distrust and a lack of 
knowledge about research in the health-interested 
public. For example, fewer than 10% of patients with 
cancer participate in clinical trials and 75% of Phase 
II−IV studies are delayed due to slow patient recruit-
ment[3]. Previous health-related scandals and the sub-
sequent bad image of the pharmaceutical industry 
could be some reasons for a lack of collaboration be-
tween patients and the industry. Another reason could 
be that patient knowledge about clinical trials and the 
medicines R&D process is low, and thus patients lack 
the confidence to get involved. 
Research shows that patients who take part in mak-
ing decisions about their healthcare are more likely to 
have better outcomes[4]. Put simply, it seems that the 
more information patients have about healthcare, the 
better they can make decisions about what is best for 
them. Nonetheless, patients can be largely unaware 
about the process of medicines R&D, even as they 
seek up-to-date, credible, and understandable informa-
tion about innovation in treatments. In a similar man-
ner, patient representatives have an increasingly com-
plex task of advising on a number of items such as 
protocol design, informed consent, marketing autho-
rization and health policies, even though they may 
have gaps in the education and the training required to 
participate as an equal partner in medicines R&D. 
2. Patient Involvement in Medicines Research 
and Development  
Patient involvement in all aspects of medicines R&D 
makes sense, and it can be across all stages of the re-
search cycle in medicines and research−right from 
early research, clinical trials, health technology as-
sessments (HTA) and regulatory processes through to 
the dissemination of information to clinicians, patients 
and patient organisations[5]. Patients can bring invalu-
able first-hand knowledge of their disease states and 
treatments and contribute to achieve meaningful solu-
tions and benefits. 
Thus, it can be argued that patient involvement is 
essential as it allows patients’ perspectives to be con-
sidered when generating new medicines of value. Pa-
tient involvement will ensure that research topics 
identified are the relevant ones to both the patient 
population and the researchers. Moreover, involved 
patients can contribute to shaping outcomes that are 
significant to them. Working in partnership with pa-
tients may also mean access to a group of patients, 
which might otherwise have been beyond reach (for 
example, a rare disease patient group). Trust and 
openness within the partnership can create value and 
result in a network, allowing access to vital insights 
and information for the research community. 
Previous successful examples of patient-guided re-
search exist, and well-established patient organisations, 
such as those from the HIV/AIDS, oncology and Par-
kinson’s communities, have demonstrated the value of 
patient involvement in medicines R&D. The coming 
together of the wider community and patient networks 
were made possible by having informed patients as 
partners. A concrete example is the European Com-
munity Advisory Board (ECAB), a working group of 
European AIDS Treatment Group (EATG), which was 
established to facilitate interaction between the com-
munity of people living with HIV and AIDS and the 
pharmaceutical industry[6]. In another case, the Dutch 
Cancer Society has a patient advisory committee, 
which is involved in the review of clinical trials. The 
participation of this group has confirmed that patients’ 
perspective is very valuable in improving the design 
of clinical research[7]. 
As patient involvement increases and academic and 
industry collaborators seek to engage more patients, 
there will be a greater need for patient advocates and 
experts who can contribute to medicines R&D, clini-
cal research and regulatory processes. However, a lack 
of such trained advocates has been previously high-
lighted. For example, the PatientPartner project iden-
tified a shortage of training opportunities for develop-
ing patient experts[8].  
3. What is EUPATI? 
The European Patients’ Academy on Therapeutic In-
novation (EUPATI) was established to bridge this gap, 
and deliver the education and training needed for in-
creasing patient involvement across Europe. EUPATI 
is a public−private partnership receiving support from 
the Innovative Medicines Initiative (IMI) Joint Under-
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taking, resources of which are composed of financial 
contribution from the European Union’s Seventh Fra-
mework Programme (FP7/2007-2013) and European 
Federation of Pharmaceutical Industries and Associa-
tions (EFPIA) companies[9]. EUPATI is a five-year 
project, launched in February 2012[10].  
Importantly, it is a patient-led partnership, coordi-
nated by the European Patients’ Forum (EPF), with 
the EGAN, the European Organisation for Rare Dis-
eases (EURORDIS) and EATG in key roles. It com-
prises of a multi-stakeholder consortium of patient 
advocates, academia, industry, and not-for- profit or-
ganisations. Thirty organisations pledged support at 
the outset, and this number has risen as coun-
try-specific EUPATI networks are being established 
across the twelve European partner countries–Austria, 
Belgium, France, Germany, Ireland, Italy, Luxem-
bourg, Malta, Poland, Spain, Switzerland and the UK.  
EUPATI aims to increase the number of well-infor-
med and trained patients to be effective advocates in 
medicines R&D. Educational material will be pro-
vided in seven European languages, targeting the pre-
viously mentioned twelve European countries. These 
materials will be used for capacity building among 
patients as well as to inform the health-interested public. 
The topics that EUPATI will cover are: (i) Discov-
ery of Medicines and Planning of Medicines Devel-
opment, (ii) Non-Clinical Testing and Pharmaceutical 
Development, (iii) Exploratory and Confirmatory 
Clinical Development, (iv) Clinical Trials, (v) Regu-
latory Affairs, Medicinal Product Safety, Pharmacovi-
gilance and Pharmacoepidemiology, and (vi) HTA 
principles and practices. The EUPATI project will also 
provide indirect benefits to other stakeholders, such as 
national agencies and regulators who are able to have 
a wider pool of patients for interaction purposes (e.g. 
to represent patient views on review boards)[11]. Con-
sequently, informed patients are able to engage confi-
dently with decision makers at the European and na-
tional levels. 
4. EUPATI’s Governance and Goals 
In order to achieve EUPATI’s goals, there is a strict 
governance structure in place. Additionally, transpa-
rency and independence are upheld rigorously at EU-
PATI. The robust governance structure includes key 
umbrella patient organisations (such as EPF, EATG 
and EURORDIS), a multidisciplinary project advisory 
board, a regulatory advisory panel and an ethics panel, 
comprising of experts in ethics, law, drug develop-
ment, regulatory affairs, evidence-based medicine and 
patient advocacy. This sets a thorough framework, 
which guides the rules for confidentiality, data privacy, 
declaration of interest, social research, ethical review 
and publications. EUPATI focuses on general aspects 
of the R&D processes to develop new medicines 
(Figure 1), and it has seven working groups with spe-
cific tasks and responsibilities (Figure 2).  
It takes on average twelve years and costs up to 
$2.6 billion[12] to carry out necessary R&D processes 
before a new medicine is available for patients. Ap-
proximately only one in ten of all development com-
pounds entering phase I clinical trials will make it 
through the whole development process and reach the 
market[13]. The success rates may vary within indica-
tions, with the highest for infectious disease products 
(17%) and the lowest for oncology products (7%). The 
main reason for discontinuation of development com-
pounds is lack of efficacy or safety, although feasibil-
ity of commercial potential can also be a cause[13]. 
EUPATI’s educational material covers neither dis-
ease-specific nor product-specific topics, but general 
themes related to processes, complexities and challen-
ges in the development of medicines. Hence, the edu-
cational material reflects a broader spectrum of topics 
related to medicines research (such as diagnostics and 
biomarkers), clinical development (such as phases of 
clinical trials) and market authorization and HTA. 
EUPATI aims to reach three types of audiences, namely 
expert patients, advocacy leaders and the health-inter-
ested lay public in twelve European countries (Figure 3). 
By January 2017, EUPATI will reach out to three 
different audiences: the first level training for one 
hundred patient experts through e-learning and 
face-to-face classroom style teaching. This course, 
offered in English, will cover general themes related 
to the medicines R&D process. The second level is an 
educational toolbox, targeting 12,000 patient advo-
cates. It will be possible to download different types 
of learning materials in seven European languages. 
The third level aims to reach 100,000 members of the 
health-interested public, who will have access to an 
internet library of resources on medicines R&D. The 
first audience of approximately one hundred patient 
experts will complete an intense on-line course, with 
additional face-to-face meetings, with each course 
lasting for a total of fourteen months. Three hundred 
highly qualified applications were received for the 
initial course and fifty students representing twen-
ty-one countries started in October 2014. The second  
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Figure 2. EUPATI’s governance structure. 
 
course is due to start in September 2015 and more 
than two hundred intended applications were received 
for the second student cohort.  
All resources of the EUPATI Toolbox and internet 
library will be available for re-use under the ‘creative 
commons licence’ agreement and will be available in 
seven languages: English, French, German, Italian, 
Polish, Russian and Spanish by 2016.  
EUPATI: Collaboration between patients, academia and industry to champion the informed patient in the research and… 
 
78 Journal of Medicines Development Sciences (2015)–Volume 1, Issue 1 
 
 
Figure 3. EUPATI target audiences and resources. 
 
5. EUPATI’s Survey on Current European 
Public Knowledge about Medicines R&D 
EUPATI carried out a survey of 6,931 members of the 
public across Europe, to explore public knowledge of 
and interest in learning more about medicines R&D in 
six European countries[14]. Over 75% of respondents 
reported having no or less than good knowledge of 
medicines R&D and any knowledge present appeared 
to decrease with age. Those who were currently or had 
previously been involved in medical research were 
almost four times more likely to report good know-
ledge of medicines R&D overall (43% vs. 13%). Par-
ticipants were most interested in learning more about 
medicine safety and personalised and predictive medi-
cine and least interested in pharmacoeconomics.  
Older people, women and those with medical re-
search experience were most interested in learning 
more about medicines R&D. The survey concluded 
that some groups may need to be specifically targeted 
to increase their awareness of medicines R&D. For 
example, women expressed great interest in learning 
more but reported less knowledge than men and it 
may be useful to explore further the views of those 
who are currently disinterested in further learning. 
Based on these findings, the authors concluded that 
without increasing patient and public knowledge and 
awareness of their roles in the medicines R&D process, 
it would be challenging to facilitate more active en-
gagement in the actual process. The findings of this 
survey lend support to EUPATI’s aim of developing 
and disseminating objective, credible and up-to-date 
knowledge about medicines R&D and be a catalyst for 
broader patient involvement. The differences observed 
in the data between individual countries also lend 
support to the fact that materials from EUPATI will be 
adapted linguistically, as well as recognizing varying 
levels of interest in different topics by country. 
6. Current Milestones from EUPATI and Next 
Steps 
Several activities have already been initiated in order 
for EUPATI to fulfil its goal, with these activities 
raising awareness of EUPATI’s objectives. EUPATI 
has successfully conducted four annual workshops 
dealing with a broad spectrum of themes such as rele-
vant examples of patient involvement in medicines 
R&D, best practices on patient engagement in medi-
cines R&D and communication tools to reach a public 
audience on medicines R&D[15]. 
The latest workshop took place in April 2015, titled 
‘EUPATI taking off in your country: An interactive 
workshop on implementing EUPATI in your country’, 
where more than one hundred people, representing 
twenty-six countries were in attendance. Of the total 
audience, 56% were either patient advocates or from 
patient organisations, representing the strong role they 
play within the EUPATI project. The challenges of 
moving toward a more systematic approach to include 
patient involvement in R&D were discussed in detail 
in the plenary session. Three students attending the 
current EUPATI expert course also gave their views in 
an open dialogue with the audience on their perspec-
tive on the course and how they might influence their 
communities based on what they are learning and ex-
periencing. In addition, a representative from EU-
RORDIS talked about communication by using social 
media and gave some successful examples on the use 
of social media to create public awareness in health 
campaigns. A novel approach was the virtual snap-
shots video where nineteen invited participants used 
the opportunity to share their views on why patient 
involvement in medicines R&D is important and what 
is happening in their community[16].  
As a public-private partnership, EUPATI is well 
placed to further the dialogue around the strategy for 
increasing patient involvement in R&D. Leveraging 
this, EUPATI hosted a workshop with fifty-six repre-
sentatives from patient organisations and industry. The 
meeting focused on recognising concrete actions, 
which will enable patient involvement in R&D in a 
systematic and meaningful way[17]. Twenty-two case 
studies were shared by patient organisations and in-
dustry representatives in the areas of HIV, neurologi-
cal diseases, oncology, paediatrics and rare diseases. 
These formed the basis of the discussions, allowing 
participants to explore lessons from real-life examples 
and identify approaches that contributed to successful 
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outcomes. The sessions also explored the benefits of 
patient and advocate involvement, current barriers and 
relevant compliance codes and frameworks that are 
desirable for smooth and transparent partnerships with 
patients and advocates during the R&D process.  
EUPATI is also involved in organising webinars on 
topics of relevance to its network members and the 
wider research community. The first webinar titled 
‘Improving involvement of patients in clinical re-
search activities’ consisted of panelists from a patient 
organisation, a university and the pharmaceutical in-
dustry, each giving their perspectives on how best to 
include patients in clinical research. Challenges were 
discussed and solutions were proposed on how to 
overcome barriers. The second webinar, titled ‘How to 
enable meaningful patient contribution to ethical re-
view?’ discussed patient involvement in ethics com-
mittees, with presentations illustrating the different 
situations in five European countries. Further webi-
nars are planned on topics such as HTA and patient 
learning. 
Another important activity within the EUPATI 
community has been to establish EUPATI National 
Platform (ENP) networks in the twelve countries par-
ticipating in EUPATI. The overall aim of such plat-
forms is to facilitate local communication, dissemina-
tion, and awareness of patient involvement in medi-
cines R&D. As such, the ENP networks seek to attract 
widespread support from local partners including pa-
tient organisations, academia and industry, as well as 
government officials, regulatory bodies, healthcare 
professionals, social care workers and medical jour-
nalists.  
ENPs have been launched in six European countries 
(France, Ireland, Italy, Luxemborg, Spain and UK), 
with teams soon to launch in Austria, Malta, Poland 
and Switzerland. The ENPs grow from three national 
representatives, one each from a patient organization, 
academia and industry, with the patient organization 
representative playing a leading role into a broad 
platform, or network, of national parters interested in 
patient involvement. Lastly, an upcoming activity is 
the development of the EUPATI Ambassador program. 
This program aspires to create key communicators 
between EUPATI and the wider public, especially with 
patient and healthcare communities, in sharing the 
mission and vision of EUPATI.  
7. Conclusion  
Medicines research and development is starting to 
revolve around the patient and patient involvement in 
related activities is becoming a reality. It follows that 
access to informed patients who can confidently par-
ticipate in multi-stakeholder collaborations is neces-
sary. While established patient organisations can pro-
vide the needed education and trainings, EUPATI, as an 
alternative resource is well on its way to offer credible 
resources. The first cohort of students are now more 
than half way through the initial EUPATI training 
course and the selection process for the second cohort 
is complete to start the course in September 2015. The 
next milestone in the EUPATI project is the launch of 
the EUPATI Toolbox in January 2016. This will enable 
EUPATI to make educational and training materials 
available for a target audience of 12,000 patient ad-
vocates in seven languages serving the twelve Euro-
pean countries. The third goal is an ambitious one: To 
increase awareness of medicines research and devel-
opment in 100,000 members of the health-interested 
public across Europe. However, positive feedback 
from the annual workshops, launch of ENPs, webinars 
and the many enthusiastic stakeholders who are sup-
portive of the EUPATI project, gives the EUPATI 
consortium confidence in achieving this goal.  
Ultimately, the availability of education and train-
ing materials will permit capacity building of patients 
and their representatives to make a positive contribu-
tion to the medicines R&D process, in collaboration 
with industry and academia. The successful uptake of 
EUPATI’s materials will hopefully translate into a new 
paradigm of increased patient involvement across the 
entire medicines research and development process, 
bringing mutual benefit, including better medicines, to 
all stakeholders. 
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